Identification of glial-cell-line-derived neurotrophic factor-regulated proteins of striatum in mouse model of Parkinson disease

Proteomics - Clinical Applications

Volumn 3, Issue 9, 2009, Pages 1072-1083

  Hong, Zhen ^a   Liu, Jun ^a   Xia, Li ^a   Pan, Jing ^a   Xiao, Qin ^a   Lu, Guaqiang ^a   Liang, Liang ^a   Chen, Sheng Di ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

DIGE; Glial cell line derived neurotrophic factor; Parkinson's disease; Striatum

Indexed keywords

CELL PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR REGULATED PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 71; MITOCHONDRIA ASSOCIATED PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CELL DIFFERENTIATION; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL IN GEL ELECTROPHORESIS; DOWN REGULATION; GEL ELECTROPHORESIS; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

PARKINSONIA;

EID: 70350765302     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800234     Document Type: Article

References (41)

1. Adolfsson, R., Gottfries, C. G., Roos, B. E., Winblad, B., Postmortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J. Neural Transm. 1979, 45, 81-105.
2. Kish, S. J., Shannak, K., Hornykiewicz, O., Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318, 876-880.
3. Ibi, T., Sahashi, K., Ling, J., Marui, K., Mitsuma, T., [Immunostaining of mitochondrial heat shock proteins (mtHSPs) in skeletal muscle fibers of mitochondrial cytopathy]. Rinsho Shinkeigaku 1996, 36, 61-64.
4. Date, I., Aoi, M., Tomita, S., Collins, F., Ohmoto, T., GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. Neuroreport 1998, 9, 2365-2369.
5. Tomac, A., Lindqvist, E., Lin, L. F., Ogren, S. O. et al., Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373, 335-339.
6. Date, I., Shingo, T., Yoshida, H., Fujiwara, K. et al., Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant. 2001, 10, 397-401.
7. Kordower, J. H., In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann. Neurol. 2003, 53, S120-S132; discussion S132-S124.
8. Yasuhara, T., Shingo, T., Muraoka, K., Kobayashi, K. et al., Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J. Neurosurg. 2005, 102, 80-89.
9. Love, S., Plaha, P., Patel, N. K., Hotton, G. R. et al., Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 2005, 11, 703-704.
10. Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K. et al., Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9, 589-595.
11. Patel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N. et al., Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005, 57, 298-302.
12. Slevin, J. T., Gerhardt, G. A., Smith, C. D., Gash, D. M. et al., Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102, 216-222.
13. Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A. S. et al., Functional receptor for GDNF encoded by the c-ret protooncogene. Nature 1996, 381, 785-789.
14. Durbec, P., Marcos-Gutierrez, C. V., Kilkenny, C., Grigoriou, M. et al., GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996, 381, 789-793.
15. Treanor, J. J., Goodman, L., de Sauvage, F., Stone, D. M. et al., Characterization of a multicomponent receptor for GDNF. Nature 1996, 382, 80-83.
16. Ibi, T., Sahashi, K., Jing, L., Zhang, G., Mitsuma, T., [Immunostaining of anti-Bcl-2 antibody in diseased human muscles]. Rinsho Shinkeigaku 1996, 36, 735-740.
17. Baloh, R. H., Gorodinsky, A., Golden, J. P., Tansey, M. G. et al., GFRalpha3 is an orphan member of the GDNF/neurturin/persephin receptor family. Proc. Natl. Acad. Sci. USA 1998, 95, 5801-5806.
18. Klein, R. D., Sherman, D., Ho, W. H., Stone, D. et al., A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 1997, 387, 717-721.
19. Enokido, Y., de Sauvage, F., Hongo, J. A., Ninkina, N. et al., GFR alpha-4 and the tyrosine kinase Ret form a functional receptor complex for persephin. Curr. Biol. 1998, 8, 1019-1022.
20. Heikkila, R. E., Hess, A., Duvoisin, R. C., Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224, 1451-1453.
21. Langston, J. W., Ballard, P., Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 1984, 11, 160-165.
22. Betarbet, R., Sherer, T. B., Greenamyre, J. T., Animal models of Parkinson's disease. Bioessays 2002, 24, 308-318.
23. Du, Y., Li, X., Yang, D., Zhang, X. et al., Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp. Biol. Med. (Maywood) 2008, 233, 881-890.
24. Ye, M., Chen, S.,Wang, X., Qi, C. et al., Glial cell line-derived neurotrophic factor in bone marrow stromal cells of rat. Neuroreport 2005, 16, 581-584.
25. Hong, Z., Wang, G., Gu, J., Pan, J. et al., Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice. Eur. J. Neurosci. 2007, 26, 1500-1508.
26. Weeks, M. E., Sinclair, J., Jacob, R. J., Saxton, M. J. et al., Stress-induced changes in the Schizosaccharomyces pombe proteome using two-dimensional difference gel electrophoresis, mass spectrometry and a novel integrated robotics platform. Proteomics 2005, 5, 1669-1685.
27. Liu, J., Hong, Z., Ding, J., Liu, J. et al., Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies. J. Proteome Res. 2008, 7, 2033-2049.
28. Pozas, E., Ibanez, C. F., GDNF and GFRalpha1 promote differentiation and tangential migration of cortical GABAergic neurons. Neuron 2005, 45, 701-713.
29. Airaksinen, M. S., Saarma, M., The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3, 383-394.
30. Manie, S., Santoro, M., Fusco, A., Billaud, M., The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 2001, 17, 580-589.
31. Sariola, H., Saarma, M., Novel functions and signalling pathways for GDNF. J. Cell Sci. 2003, 116, 3855-3862.
32. Meng, X., Lindahl, M., Hyvonen, M. E., Parvinen, M. et al., Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 2000, 287, 1489-1493.
33. Mwangi, S., Anitha, M., Fu, H., Sitaraman, S. V., Srinivasan, S., Glial cell line-derived neurotrophic factor-mediated enteric neuronal survival involves glycogen synthase kinase-3beta phosphorylation and coupling with 14-3-3. Neuroscience 2006, 143, 241-251.
34. Jin, J., Hulette, C., Wang, Y., Zhang, T. et al., Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics 2006, 5, 1193-1204.
35. Shi, M., Jin, J., Wang, Y., Beyer, R. P. et al., Mortalin: a protein associated with progression of Parkinson disease? J. Neuropathol. Exp. Neurol. 2008, 67, 117-124.
36. Van Laar, V. S., Dukes, A. A., Cascio, M., Hastings, T. G., Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 2008, 29, 477-489.
37. Ryu, E. J., Harding, H. P., Angelastro, J. M., Vitolo, O. V. et al., Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 2002, 22, 10690-10698.
38. Dauer, W., Przedborski, S., Parkinson's disease: mechanisms and models. Neuron 2003, 39, 889-909.
39. Fukui, H., Moraes, C. T., The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? Trends Neurosci. 2008, 31, 251-256.
40. Politi, L. E., Rotstein, N. P., Carri, N. G., Effect of GDNF on neuroblast proliferation and photoreceptor survival: additive protection with docosahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 2001, 42, 3008-3015.
41. Petrak, J., Ivanek, R., Toman, O., Cmejla, R. et al., Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. pu Proteomics 2008, 8, 1744-1749.